Nutzen Sie unser Angebot ohne Werbetracking durch Dritte für 4,99 Euro/Monat. Kunden mit einem bestehenden Abo (Tageszeitung, ePaper oder MP+) erhalten das PUR-Abo zum Vorzugspreis von 1,99 EUR ...
In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
The serine/threonine kinase AKT is a key component of the PI3K/AKT/mTOR signaling pathway as it exerts a pivotal role in cell growth, proliferation, survival, and metabolism. Deregulation of this ...
TecDax 3.678 10:53:45-0,93% 10:53:45 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback